Skip to content

Time until relapse after augmentation with single‐dose ketamine in treatment‐resistant depression

R. Pérez-Esparza, T. Corona, R. Ruiz-García, Nelcy Oñate-Cadena, C. de la Fuente-Sandoval, J. Ramírez-Bermúdez

Psychiatry and Clinical Neurosciences June 19, 2018 DOI: 10.1111/pcn.12675 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Intervention Ketamine
Topics Depression Esketamine Ketamine
Key findings Ketamine produces rapid antidepressant effects in treatment-resistant depression, with most studies reporting response up to 7 days and remission up to 3-5 days after a single dose, measured after treatment washout. The authors present this as a promising advance for TRD therapeutics.

Abstract

Growing evidence of the rapid antidepressant effects of ketamine represents a promising advance in treatment-resistant depression (TRD) therapeutics. Most studies provide information after treatment washout, reporting response up to 7 days and remission up to 3-5 days after a single dose.

Comparable studies

Other narrative reviews on ketamine for depression, most cited first.

Study Year Design Participants
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression 2021 Review
Ketamine: a paradigm shift for depression research and treatment 2019 Review
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective 2019 Review
Ketamine: A tale of two enantiomers 2020 Review
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor 2021 Review

Citations in the library

Cited by 1

Cites 2

Related reading

Explore topics

Depression Esketamine Ketamine

By condition and practice

Ketamine for depression